Claris Injectables
Ahmedabad
About Claris Injectables
Claris Injectables Limited, a wholly-owned subsidiary of Claris Lifesciences Limited - collectively ‘Claris’, is a sterile injectables pharmaceutical company with its market presence across the world. Claris manufactures and/or markets products across multiple delivery systems, markets, and therapeutic segments, including anesthesia & analgesics, blood products, anti-infectives, critical care, and nephrology. A significant majority of these products are generic drugs, capable of being directly injected into the human body, predominantly used in the treatment of critical illnesses. Our customer base primarily includes government and semi-government institutions, group corporate hospitals, standalone prominent hospitals, and nursing homes. With emphasis on quality, technology, and innovation, we offer a range of niche technology-driven injectables products across delivery systems, such as bags (PVC & NPVC), vials, ampoules, glass bottles, etc. We have three manufacturing facilities at a campus located in Ahmedabad, India. Our sterile injectables facilities have been approved by regulatory authorities, including US FDA, MHRA (UK), TGA (Australia), MCC (South Africa), ANVISA (Brasil), INVIMA (Colombia), and GCC FDCA. Our manufacturing capabilities have enabled us earn several awards from prestigious institutions like IDMA (Indian Drug Manufacturers' Association) and Frost & Sullivan IMEA (India Manufacturing Excellence Award). Our capabilities and experience span across several business verticals in the specialty injectables industry. We have a trained workforce extending over all the business functions, such as product development, regulatory affairs for obtaining product registrations, manufacturing, and sales & marketing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Website: clarisinj.com
Canonical: https://fsome.com/organization/claris-injectables-2887112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.